Diligence memo · auto-generated · as of July 2, 2026
TYBR Health, Inc.
TYBR Health, Inc. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
TYBR Health, Inc. operates in Biotechnology, based in HOUSTON, TX, USA. Natural hydrogel to keep internal organs scar-free after surgery
Sub-sector tags: B2B, Medical Devices.
Capital & rounds (filed)filed
TYBR Health, Inc. has raised $7.9M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.1M on 2025-01-17.
Most recent recorded round closed around 2025-01-17.
Valuation (modeled)modeled
Provath models TYBR Health, Inc. at approximately $29M (range $7.8M–$55M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.84× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 25 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
The last round stepped up 6.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 51% of Biotechnology peers (4293 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.